ONCOLYTIC VIRUS FOR
BRAIN TUMOURS
GBM has failed every immune approach β except this one. PVSRIPO's 21% OS at 36 months against 4% historical control is the most important signal to emerge from recurrent GBM research.
Why GBM Is the Strongest Rationale
GBM is one of oncology's most immunologically cold tumours β dominated by immunosuppressive M2 macrophages and myeloid-derived suppressor cells. Checkpoint inhibitors have failed in multiple Phase III trials. Extreme cold tumour biology is exactly where oncolytic virus mechanism has the strongest theoretical rationale.
βThe blood-brain barrier is irrelevant here β the neurosurgeon already operates on the tumour. PVSRIPO and DNX-2401 are delivered by direct intratumoral injection during or after surgery.β
Key GBM Data
- 21%OS at 36 months (PVSRIPO)Versus ~4% historical control in recurrent GBM.
- ~12%3-year OS (DNX-2401)Versus near-zero historical baseline.
- Phase IIIPVSRIPO StatusOngoing at Duke and affiliated sites.
GBM Oncolytic Virus Programmes
PVSRIPO
Poliovirus with IRES replaced by rhinovirus 2 IRES β eliminates neurovirulence, preserves oncolysis. Targets CD155 on GBM cells and immunosuppressive macrophages. Pre-treatment polio vaccination required. Phase III ongoing at Duke.
DNX-2401 (Tasadenoturev)
Adenovirus selective for Rb-deficient cells (majority of GBM). ~12% 3-year OS. Being combined with pembrolizumab β viral inflammation + checkpoint inhibition.
G207 (HSV-1 Derivative)
Most significant data from paediatric high-grade glioma trials. Phase II showed radiological and clinical responses in children with DIPG β a disease where nothing currently produces objective responses.
Frequently Asked Questions
GBM Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Interested in Oncolytic Virus for Brain Tumors?
Upload your medical reports for a free evaluation. Our team will identify the most relevant oncolytic virus programmes and clinical trials for your specific diagnosis.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.